Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Gonçalves (Coimbra, Portugal), S. Cabral (Coimbra, Portugal), A. Lopes (Coimbra, Portugal). Annual FEV1% variation before and after augmentation therapy in severe alpha-1-antitrypsin deficiency. 4238

Member's Comments

No comment yet.

Related content which might interest you: Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Long-term effect of a1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database Source: ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021 Year: 2021 Intermediate and severe α1-antitrypsin deficiency: influence on plasma α1-antitrypsin, FEV1 and risk of COPD. Three meta-anlyses Source: Eur Respir J 2002; 20: Suppl. 38, 513s Year: 2002 Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Lung function decline in relation to alpha-1-antitrypsin phenotypes in severe asthma Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003 One year follow-up of intrabronchial lung volume reduction in alpha-1-antitrypsin deficiency and severe emphysema Source: Annual Congress 2011 - Treatment beyond inhalers: endoscopic lung volume reduction Year: 2011 Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough Source: Eur Respir J 2016; 47: 35-38 Year: 2016 Use of measurements of airway resistance in the determination of reversibility in patients with emphysema associated with alpha-1-antitrypsin (A1ATD) deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 205s Year: 2001 Mortality versus FEV1, KCO and CT lung density measured at baseline in the UK alpha-1-antitrypsin deficiency assessment programme Source: Eur Respir J 2001; 18: Suppl. 33, 91s Year: 2001 Changes in FEV1 and SpO2 in patients with severe and very severe COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Association between weight loss and decline in FVC in patients with IPF Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Current and future therapy of lung emphysema caused by alpha-1-antitrypsin deficiency Source: Annual Congress 2004 - Alpha-1-antitrypsin deficiency: Current knowledge and new frontiers Year: 2004 ADAM33 SNPs are associated with excess FEV1 decline in severe early onset COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 Decline of FEV1 in different groups of severe refractory asthmatics Source: Eur Respir J 2005; 26: Suppl. 49, 575s Year: 2005 Exploring the relationship between alpha-1-antitrypsin deficiency and persistent airflow limitation in severe asthma. Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017